PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-3.66%
Both yoy net incomes decline, with TRVN at -11.62%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
13.04%
D&A growth of 13.04% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Deferred tax of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
1.43%
Less SBC growth vs. TRVN's 7.61%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-401.62%
Both reduce yoy usage, with TRVN at -47.24%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both negative yoy AP, with TRVN at -1125.94%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-97.99%
Negative yoy usage while TRVN is 34.26%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-100.00%
Negative yoy while TRVN is 32.03%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-93.84%
Both yoy CFO lines are negative, with TRVN at -1.97%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-375.00%
Both yoy lines negative, with TRVN at -100.00%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-375.00%
Both yoy lines negative, with TRVN at -100.00%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-84.27%
Both yoy lines negative, with TRVN at -99.99%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.